Study of two drugs for Crohn's disease
Treatments studied
Part of Digestive system clinical trials.
This trial tests if taking a new drug (LY4395089) with mirikizumab works better than mirikizumab alone for adults with Crohn's disease. It also looks at the safety of these treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older with Crohn's disease.
- You must be on a stable dose if you take certain diabetes or weight-loss medicines (like Ozempic or Mounjaro).
- You cannot have liver disease or a history of other bone diseases.
- You cannot have had a heart attack, stroke, unstable angina, heart failure hospitalization, or heart procedure in the last 6 months.
- You cannot be using other medicines that are not allowed in this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing multiple new drugs for people with moderate to severe ulcerative colitis or Crohn's disease who have not had success with at least one standard treatment. The goal is to find a better option that can help control symptoms and inflammation.
This study tests a medication called mirikizumab to see if it can help people with Crohn's disease who have narrowing (strictures) in the small intestine caused by inflammation. The goal is to improve symptoms like belly pain after eating and to possibly reduce the narrowing without needing surgery.
This study tests two drugs together (LY4268989 and mirikizumab) in people with moderate to severe ulcerative colitis. It's for those whose current treatments didn't work well enough.
This study tests a new medicine called mirikizumab for people with ulcerative colitis or Crohn's disease who have not responded well to other treatments. It aims to see if mirikizumab can help control symptoms and improve quality of life.
This study tests two experimental drugs, Eltrekibart and Mirikizumab, for adults with moderate to severe ulcerative colitis who have not responded well to other treatments. The goal is to see if these drugs can help control the disease.
This study tests an investigational medication called LY4268989 for adults with moderate to severe ulcerative colitis (UC). It's for people who have tried other treatments without success. The goal is to see if the drug can reduce inflammation and improve symptoms.
Hear when a new Crohn Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.